Karah Herdman Parschauer insider trades: Ultragenyx Pharmaceutical (RARE) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Karah reports to the SEC
Open-market buys and sales
33 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | RARE | ↓ Sell | 1,900 | $24.92 | $47K | Direct | Aug 4, 2026 (1d) |
| Jun 15, 2026 | RARE | ↓ Sell | 1,899 | $24.62 | $47K | Direct | Jun 15, 2026 (0d) |
| Mar 10, 2026 | RARE | ↓ Sell | 9,526 | $21.87 | $208K | Direct | Mar 10, 2026 (0d) |
| Mar 2, 2026 | RARE | ↓ Sell | 8,135 | $22.80 | $185K | Direct | Mar 3, 2026 (1d) |
| Sep 12, 2025 | RARE | ↓ Sell | 2,450 | $31.17 | $76K | Direct | Sep 12, 2025 (0d) |
| Mar 12, 2025 | EOLS | ↓ Sell | 12,888 | $12.99 | $167K | Direct | Mar 14, 2025 (2d) |
| Mar 3, 2025 | RARE | ↓ Sell | 12,846 | $42.10 | $541K | Direct | Mar 4, 2025 (1d) |
| Feb 27, 2025 | RARE | ↓ Sell | 2,990 | $42.88 | $128K | Direct | Mar 3, 2025 (4d) |
| Jun 12, 2024 | RARE | ↓ Sell | 9,806 | $45.00 | $441K | Direct | Jun 12, 2024 (0d) |
| Mar 1, 2024 | RARE | ↓ Sell | 3,756 | $53.76 | $202K | Direct | Mar 5, 2024 (4d) |
| Jan 30, 2024 | EOLS | ↓ Sell | 11,931 | $13.14 | $157K | Direct | Feb 2, 2024 (3d) |
| May 4, 2023 | RARE | ↓ Sell10b5-1 | 4,378 | $45.00 | $197K | Direct | May 5, 2023 (1d) |
| Mar 1, 2023 | RARE | ↓ Sell | 3,161 | $45.25 | $143K | Direct | Mar 3, 2023 (2d) |
| Mar 7, 2022 | RARE | ↓ Sell | 5,140 | $62.95 | $324K | Direct | Mar 8, 2022 (1d) |
| Mar 1, 2022 | RARE | ↓ Sell | 2,886 | $66.62 | $192K | Direct | Mar 3, 2022 (2d) |
| Oct 14, 2021 | RARE | ↓ Sell | 310 | $81.14 | $25K | Direct | Oct 18, 2021 (4d) |
| Sep 8, 2021 | RARE | ↓ Sell | 7,336 | $100.65 | $738K | Direct | Sep 9, 2021 (1d) |
| Jun 10, 2021 | RARE | ↓ Sell | 1,329 | $100.00 | $133K | Direct | Jun 11, 2021 (1d) |
| May 6, 2021 | RARE | ↓ Sell | 313 | $113.67 | $36K | Direct | May 10, 2021 (4d) |
| Mar 1, 2021 | RARE | ↓ Sell | 3,970 | $138.17 | $549K | Direct | Mar 3, 2021 (2d) |
| Oct 30, 2020 | RARE | ↓ Sell | 9,903 | $100.12 | $991K | Direct | Nov 2, 2020 (3d) |
| Oct 28, 2020 | RARE | ↓ Sell | 97 | $100.00 | $10K | Direct | Oct 30, 2020 (2d) |
| Oct 14, 2020 | RARE | ↓ Sell | 325 | $88.00 | $29K | Direct | Oct 16, 2020 (2d) |
| Oct 8, 2020 | RARE | ↓ Sell | 10,000 | $95.00 | $950K | Direct | Oct 13, 2020 (5d) |
| Oct 6, 2020 | RARE | ↓ Sell | 10,000 | $90.00 | $900K | Direct | Oct 7, 2020 (1d) |
| Sep 23, 2020 | RARE | ↓ Sell | 10,000 | $85.00 | $850K | Direct | Sep 24, 2020 (1d) |
| Aug 17, 2020 | RARE | ↓ Sell | 12,370 | $88.43 | $1.1M | Direct | Aug 19, 2020 (2d) |
| May 18, 2020 | RARE | ↓ Sell | 2,722 | $74.72 | $203K | Direct | May 19, 2020 (1d) |
| Jun 24, 2019 | RARE | ↓ Sell | 2,715 | $62.33 | $169K | Direct | Jun 24, 2019 (0d) |
| Apr 29, 2019 | RARE | ↓ Sell | 468 | $68.30 | $32K | Direct | Apr 30, 2019 (1d) |
| Aug 21, 2018 | RARE | ↓ Sell | 5,000 | $78.53 | $393K | Direct | Aug 21, 2018 (0d) |
| Jun 21, 2018 | RARE | ↓ Sell | 1,226 | $82.77 | $101K | Direct | Jun 21, 2018 (0d) |
| May 10, 2018 | RARE | ↓ Sell | 1,465 | $60.00 | $88K | Direct | May 10, 2018 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other RARE insiders
Open-market trades in the last 12 months
About Karah Herdman Parschauer's insider trades
Karah Herdman Parschauer is EVP and Chief Legal Officer at Ultragenyx Pharmaceutical (RARE). Since May 10, 2018, Karah has reported no open-market purchases and 33 sales worth $10.3M on SEC Form 4. In the last 12 months: 4 sales ($488K).
1 sale (2% of the value sold) was made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so it says little about how the insider sees the stock today.
Their filings also include grants and awards (33 filings), shares withheld for taxes (10 filings), option exercises (7 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every RARE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.